But these companies are not resting with their success in the generics field and have also been engaged in drug discovery. 
The latest trends reflect a steady rise in the R&D expenditure of most of these companies who have spent billions in their quest for a new drug. Many of the top Indian companies today have an active and robust NCE program. While these may not be much when compared with the global pharma majors in terms of scale but Indian companies make this up in efficiencies and cost effectiveness. Indian companies have a distinct advantage in terms of the huge pool of scientific talent available here and the overall low cost of research. The rapidly increasing NCE research in India is attracting several expat Indian scientists to return and contribute effectively in fast tracking the NCE research in the country. Some companies are even collaborating with Big Pharma for lead molecules to fast track their discovery programs. However, most Indian companies have to build a large resource pool, both people and financial, to undertake complete development by themselves. Thus, the current trend of licensing out for full-fledged development is a small step in this direction.
But in the short term Indian companies will invest the revenues they get from the milestone payments for these NCEs to further bolster their R&D programs. Research will also generate revenue through patent challenges, assigning IP and other ways. Obviously this will help the industry expand its R&D spend over a time.
NCE research by its very nature is a long drawn out process stretching up to 20 years. Even in the normal course, it takes about five to seven years before a NCE can be commercialised. The Indian environment is slowly learning to be patient for long term, high risk drug discovery model and hopefully this will translate into more funding by investors in this area. However, as most Indian companies have embarked on their NCE research only in the last decade or so, therefore it is highly unlikely that a wholly Indian-developed and Indian-owned new drug will hit the market in the short term.
The latest trends reflect a steady rise in the R&D expenditure of most of these companies who have spent billions in their quest for a new drug. Many of the top Indian companies today have an active and robust NCE program. While these may not be much when compared with the global pharma majors in terms of scale but Indian companies make this up in efficiencies and cost effectiveness. Indian companies have a distinct advantage in terms of the huge pool of scientific talent available here and the overall low cost of research. The rapidly increasing NCE research in India is attracting several expat Indian scientists to return and contribute effectively in fast tracking the NCE research in the country. Some companies are even collaborating with Big Pharma for lead molecules to fast track their discovery programs. However, most Indian companies have to build a large resource pool, both people and financial, to undertake complete development by themselves. Thus, the current trend of licensing out for full-fledged development is a small step in this direction.But in the short term Indian companies will invest the revenues they get from the milestone payments for these NCEs to further bolster their R&D programs. Research will also generate revenue through patent challenges, assigning IP and other ways. Obviously this will help the industry expand its R&D spend over a time.
NCE research by its very nature is a long drawn out process stretching up to 20 years. Even in the normal course, it takes about five to seven years before a NCE can be commercialised. The Indian environment is slowly learning to be patient for long term, high risk drug discovery model and hopefully this will translate into more funding by investors in this area. However, as most Indian companies have embarked on their NCE research only in the last decade or so, therefore it is highly unlikely that a wholly Indian-developed and Indian-owned new drug will hit the market in the short term.
Read these article :-
ZEE BUSINESS BEST B SCHOOL SURVEY
B-schooled in India, Placed Abroad (Print Version)
IIPM in Financial times (Print Version)
IIPM makes business education truly global (Print Version)
The Indian Institute of Planning and Management (IIPM)
IIPM Campus
No comments:
Post a Comment